Ultrasound Measurement of Reactive Hyperemia in Critical Care
URHC
1 other identifier
observational
250
1 country
1
Brief Summary
The investigators hypothesize that doctors and nurses can undergo a brief period of training and then use ultrasound to accurately measure blood flow in a forearm artery after a brief period when this flow is interrupted with a blood pressure cuff, a measurement the investigators call reactive hyperemia. Reactive hyperemia indicates whether the small blood vessels in the body are healthy -- lower reactive hyperemia indicates worse small blood vessel function. When measured by experienced ultrasound experts, low reactive hyperemia strongly predicts death in critically ill patients with infection (severe sepsis). The investigators are conducting this study to determine if doctors and nurses, without specific pre-existing expertise in ultrasound, can be trained to make these measurements accurately. If so, the investigators will prove that these measurements can be applied reliably in real-world practice. The investigators also hypothesize that reactive hyperemia predict the outcomes of illness not just in patients with severe infection, but in other critically ill patients as well. Finally, the investigators hypothesize that reduced blood flow after blood pressure cuff occlusion is linked with other abnormalities of blood, previously identified in critically ill patients. For example, red blood cells from patients with severe sepsis have been shown to be stiffer than normal, so they are less able to flow along the small blood vessel passages of the body. Red blood cells become stiffer when there is a certain type of stress in the body known as "oxidative stress." If the investigators show that low reactive hyperemia, stiff red blood cells, and oxidative stress are linked, the investigators hope to develop new treatments that reduce oxidative stress, reduce the stiffness of red blood cells, and in turn improve reactive hyperemia. Improvements in reactive hyperemia indicate improvements in small blood vessel function. Better small blood vessel function means better delivery of oxygen throughout the body. The investigators believe that this will improve outcomes for critically ill patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2013
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 6, 2012
CompletedFirst Posted
Study publicly available on registry
November 15, 2012
CompletedStudy Start
First participant enrolled
January 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2019
CompletedFebruary 12, 2020
February 1, 2020
6.9 years
July 6, 2012
February 11, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
hospital mortality
vital status at hospital discharge, an expected average of 3 weeks
Study Arms (3)
severe sepsis
Patients with severe sepsis or septic shock
non-infected critically ill
Patients with severe non-infectious systemic inflammatory response syndrome
healthy
healthy volunteers
Eligibility Criteria
Critically ill Patients: Patients admitted to University of Rochester Medical Center ICU services with 2 of the 4 systemic inflammatory response syndrome (SIRS) criteria and acute organ dysfunction will be considered for enrollment. Healthy Control subjects: Healthy control subjects \>= 18 years of age will be recruited from the University and Rochester region at large.
You may qualify if:
- Patients admitted to University of Rochester Medical Center ICU services with 2 of the 4 systemic inflammatory response syndrome (SIRS) criteria and acute organ dysfunction will be considered for enrollment.
- Healthy control subjects \>= 18 years of age will be recruited from the University and Rochester region at large.
You may not qualify if:
- Critically ill patients:
- Refusal of patient or designated surrogate decision-maker to provide written informed consent, or inability to obtain consent within 48 hours of diagnosis
- Attending physician refusal
- Hematocrit (Hct) \< 21%
- Acute bleeding requiring PRBC transfusion
- History of chronic, dialysis dependent renal failure
- End-stage liver disease and Child-Pugh Grade C
- History of organ, bone marrow, or stem cell transplant
- Pregnancy
- Cardiac surgery (including ventricular assist device prior to first sample collection)
- Do not resuscitate at screening or plans for withdrawal of life support imminent
- Suicide attempt or intentional drug overdose;
- Jehovah's witness
- Healthy Control subjects:
- Absent doppler signal in brachial or radial arteries.
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Rochester Medical Center
Rochester, New York, 14642, United States
Related Publications (1)
Wexler O, Morgan MA, Gough MS, Steinmetz SD, Mack CM, Darling DC, Doolin KP, Apostolakos MJ, Graves BT, Frampton MW, Chen X, Pietropaoli AP. Brachial artery reactivity in patients with severe sepsis: an observational study. Crit Care. 2012 Dec 12;16(2):R38. doi: 10.1186/cc11223.
PMID: 22390813BACKGROUND
Biospecimen
Blood and urine specimens will be obtained within 48 hours of diagnosis of severe sepsis or severe non-infectious systemic inflammatory response syndrome. Subsequent blood and urine samples will be obtained 3-5 days after the first set of samples, within 48 hours of ICU discharge, and within 48 hours of hospital discharge. Samples will analyzed immediately or stored at -80 degrees celsius until use.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anthony P. Pietropaoli, M.D., M.P.H.
University of Rochester
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Medicine
Study Record Dates
First Submitted
July 6, 2012
First Posted
November 15, 2012
Study Start
January 1, 2013
Primary Completion
December 1, 2019
Study Completion
December 1, 2019
Last Updated
February 12, 2020
Record last verified: 2020-02